Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Instituto Aragones de Ciencias de la Salud (IACS), Zaragoza, Spain.
Instituto de Investigación Sanitaria (IIS) Aragon, Zaragoza, Spain.
FASEB J. 2022 Aug;36(8):e22429. doi: 10.1096/fj.202200118RR.
Obesity is a major risk factor for the development of Nonalcoholic fatty liver disease (NAFLD). We hypothesize that a dysfunctional subcutaneous white adipose tissue (scWAT) may lead to an accumulation of ectopic fat in the liver. Our aim was to investigate the molecular mechanisms involved in the causative role of scWAT in NALFD progression. We performed a RNA-sequencing analysis in a discovery cohort (n = 45) to identify genes in scWAT correlated with fatty liver index, a qualitative marker of liver steatosis. We then validated those targets in a second cohort (n = 47) of obese patients who had liver biopsies available. Finally, we obtained scWAT mesenchymal stem cells (MSCs) from 13 obese patients at different stages of NAFLD and established in vitro models of human MSC (hMSC)-derived adipocytes. We observed impaired adipogenesis in hMSC-derived adipocytes as liver steatosis increased, suggesting that an impaired adipogenic capacity is a critical event in the development of NAFLD. Four genes showed a differential expression pattern in both scWAT and hMSC-derived adipocytes, where their expression paralleled steatosis degree: SOCS3, DUSP1, SIK1, and GADD45B. We propose these genes as key players in NAFLD progression. They could eventually constitute potential new targets for future therapies against liver steatosis.
肥胖是导致非酒精性脂肪性肝病(NAFLD)的一个主要危险因素。我们假设,功能失调的皮下白色脂肪组织(scWAT)可能导致肝脏内异位脂肪的积累。我们的目的是研究 scWAT 在 NALFD 进展中起因果作用的分子机制。我们对一个发现队列(n=45)进行了 RNA 测序分析,以确定与肝脂肪指数相关的 scWAT 基因,肝脂肪指数是肝脂肪变性的定性标志物。然后,我们在另一批(n=47)有肝活检的肥胖患者中验证了这些靶点。最后,我们从 13 名处于不同阶段的 NAFLD 肥胖患者中获得了 scWAT 间充质干细胞(MSCs),并建立了人 MSC(hMSC)衍生的脂肪细胞的体外模型。我们观察到随着肝脂肪变性的增加,hMSC 衍生的脂肪细胞中的脂肪生成受损,这表明脂肪生成能力受损是 NAFLD 发展的一个关键事件。有四个基因在 scWAT 和 hMSC 衍生的脂肪细胞中表现出不同的表达模式,它们的表达与脂肪变性程度平行:SOCS3、DUSP1、SIK1 和 GADD45B。我们提出这些基因是 NAFLD 进展的关键因素。它们最终可能成为针对肝脂肪变性的未来治疗的潜在新靶点。